Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease
V Coric, CH Van Dyck, S Salloway… - Archives of …, 2012 - jamanetwork.com
Objective To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic
effects of the γ-secretase inhibitor avagacestat in patients with mild to moderate Alzheimer
disease (AD). Design Randomized, double-blind, placebo-controlled, 24-week phase 2
study. Setting Global, multicenter trial. Patients A total of 209 outpatients with mild to
moderate AD were randomized into the double-blind treatment phase. The median age of
the patients was 75 years, 58.9% were APOE ϵ4 carriers, and baseline measures of …
effects of the γ-secretase inhibitor avagacestat in patients with mild to moderate Alzheimer
disease (AD). Design Randomized, double-blind, placebo-controlled, 24-week phase 2
study. Setting Global, multicenter trial. Patients A total of 209 outpatients with mild to
moderate AD were randomized into the double-blind treatment phase. The median age of
the patients was 75 years, 58.9% were APOE ϵ4 carriers, and baseline measures of …